The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Involving regional centres in the management of MDS and AML to improve access to care
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, highlights the importance of involving regional centres in the management of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), enabling equitable access to care and clinical trials in Australia. By providing services, including clinical treatments and trials, in regional environments, patients can receive ongoing care closer to home, overcoming the “tyranny of postcode” and improving outcomes. This approach also benefits larger hospitals by sharing the workload, resulting in a win-win situation for both healthcare providers and patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is really excellent work led by my colleague Dr Michael Ashby who works across our centre but also in a regional centre and gave us a really good insight into being able to provide care for myeloid malignancies across two centres. One servicing a large metropolitan community and then utilising that to help service patients in a regional area but importantly by delivering services including clinical treatments and clinical trials in the regional environment, meaning that patients are not having to spend long periods of time away from home...
So this is really excellent work led by my colleague Dr Michael Ashby who works across our centre but also in a regional centre and gave us a really good insight into being able to provide care for myeloid malignancies across two centres. One servicing a large metropolitan community and then utilising that to help service patients in a regional area but importantly by delivering services including clinical treatments and clinical trials in the regional environment, meaning that patients are not having to spend long periods of time away from home. What it did show is that it helps us overcome the tyranny of postcode that often impacts patients who come from the regions by being able to be treated both in a specialist centre for those times where they needed high-intensity therapies, but then receive their ongoing care closer to home. It really did facilitate better outcomes for this group of patients and it helps the larger hospitals by being able to share the workload for these regional patients with the regional centres so it’s a win-win for both the healthcare providers but also most importantly patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
